WO2018059211A1 - 精胺及其衍生物的新应用 - Google Patents

精胺及其衍生物的新应用 Download PDF

Info

Publication number
WO2018059211A1
WO2018059211A1 PCT/CN2017/101059 CN2017101059W WO2018059211A1 WO 2018059211 A1 WO2018059211 A1 WO 2018059211A1 CN 2017101059 W CN2017101059 W CN 2017101059W WO 2018059211 A1 WO2018059211 A1 WO 2018059211A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceutically acceptable
compound
derivative
spermine
Prior art date
Application number
PCT/CN2017/101059
Other languages
English (en)
French (fr)
Inventor
潘武广
朱威
Original Assignee
广州君赫生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州君赫生物科技有限公司 filed Critical 广州君赫生物科技有限公司
Priority to EP17854661.0A priority Critical patent/EP3520770A4/en
Priority to JP2019516530A priority patent/JP6870077B2/ja
Priority to US16/334,273 priority patent/US10709676B2/en
Publication of WO2018059211A1 publication Critical patent/WO2018059211A1/zh
Priority to US16/889,500 priority patent/US20200297660A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/57—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with a further substituent in position 7, e.g. cephamycines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/90—Antimony compounds

Definitions

  • This invention relates to new applications of spermine and its derivatives.
  • Anthraquinone anabolism is a ubiquitous and important biological metabolism in organisms. Its products AMP and GMP not only provide raw materials for the biosynthesis of DNA and RNA in vivo, but also many key coenzymes in the body (NAD, NADP, FAD and CoA). ), signaling molecules (such as cAMP) and the important energy molecule ATP provide the purine bases necessary for its synthesis. It can be seen that hydrazine anabolism is at the core of the entire metabolic network. Indole synthesis includes two synthetic pathways, de novo purine synthesis and salvage pathway.
  • Adenyl succinate lyase deficiency (adenylosuccinatelyase deficiency ADSL deficiency) is a metabolic disorder in which adenine de novo synthesis and purine nucleotide metabolism pathways produce deletions and disorders.
  • the cause of the disease is mainly due to mutation or deletion of adenyl succinate lyase in the patient, resulting in excessive accumulation of the enzyme substrate SAICAR in the cell without timely clearance [Jaeken J, Van den Berghe G. (1984). An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids. Lancet 8411: 1058-1061.].
  • Adenylosuccinatelyase deficiency an unusual cause of neonatal seizure.
  • Arch Pediatr 15 135-138.
  • Screening for adenylosuccinatelyase deficiency clinical, biochemical and molecular findings in four patients. Neuropediatrics 33, 186-189.
  • ADSL deficiency has three consecutive major phenotypes: neonatal lethal, severe (type I) and mild to moderate (type II). It has been clinically found that even patients from the same family have different phenotypes. The onset is generally seen in the period from birth to infancy. The reported cases have fatal neonatal brain lesions (representing hypokinesia, refractory epilepsy, respiratory disorders), moderate intelligence Force defect. All patients have mental retardation, most of them have different types of epilepsy, and about one-third of them have autistic features (no eye contact, sensitivity to sound and light, repetitive behavior, agitation, temper tantrum, self-injury and Self-mutilation).
  • Clinical manifestations include delayed mental activity, hyperactivity, speech disorders, muscle tone loss, muscle atrophy, and paralysis. Severe patients usually have microcephaly. Prenatal clinical manifestations include: intrauterine growth impaired, microcephaly, fetal motor dysfunction, and fetal heart rate loss.
  • ADSL enzyme adenyl succinate lyase
  • SAICAr is the product of SAICAR dephosphorylation
  • S-Ado is the product of S-AMP dephosphorylation
  • PAICS phosphoribosylaminoimidazolesuccinocarboxamidesynthetase/phosphoribosylaminoimidazolecarboxylase
  • SAICAR synthetase (4 -(N-succinylcarboxamide)-5-aminoimidazole ribonucleotidesynthetase, SAICARs) and AIR carboxylase (AIRc) function, catalyze the de novo catabolism of the sixth and seventh steps, one of the key reaction processes As follows
  • spermine is a polyamine containing two amino groups and two imino groups. It is produced by a variety of enzymes in the living body by putrescine (butanediamine) and S-adenosylmethionine. Both it and spermidine are present in bacteria and most animal cells and are important substances that promote cell proliferation. Under acidic conditions, it exhibits polycationic polyamine properties and is capable of binding to DNA in viruses and bacteria. It gives DNA molecules greater stability and flexibility and is one of the essential components in cell culture fluids. Spermine has been used as a nutritional supplement.
  • the inventors found that the DrugBank ID DB00127 compound (spermine) can effectively interfere with the activity of PAICS, thereby reducing the synthesis of SAICAR and ultimately reducing the accumulation of SAICAr. To achieve the purpose of treating or improving ADSL deficiency.
  • the pharmaceutically acceptable derivative of the above compound has the same core structure as the compound itself, and undergoes hydrolysis or the like in the body to form a molecule having the same or similar activity as the original compound, achieving the same or similar therapeutic effects.
  • a pharmaceutically acceptable derivative of a compound especially a simple derivative thereof, particularly one of a lower ester, a lower ether, a lower alkyl substituent, a pharmaceutically acceptable salt, or a lower amide, that is, having 1 to 6 carbon atoms.
  • it is a carboxylic acid of 2 to 6, 2 to 4,
  • compositions of the compounds can be synthesized from the parent compound by conventional chemical methods, such as in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: The method described in 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • these salts can be prepared by reacting the free base of the compound with an acid in water or an organic solvent or a mixture of the two; usually, a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is used. .
  • Acid addition salts can be prepared by various acids (mineral acids and organic acids).
  • the acid addition salt include a salt made of an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), and L-aspartate.
  • benzenesulfonic acid benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, citric acid, hexanoic acid, Octanoic acid, cinnamic acid, citric acid, cyclaic acid, lauryl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactose Acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (such as D-glucuronic acid), glutamic acid (such as L-glutamic acid), ⁇ -ketoglutaric acid, glycolic acid, Hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionate
  • Figure 1 is a three-dimensional solid ribbon structure diagram of PAICS
  • FIG. 2 is a diagram showing the interaction of CAIR and SAICAR synthetase in crystal structure, in which A: PDB access ID 2GQS; B: PDB access ID 2CNQ; C: PDB access ID 4FE2;
  • Figure 3 is a result of alignment of different SAICAR synthase protein sequences.
  • the human PAICS protein sequence has a total length of 425 amino acid residues, of which 2 to 260AA is the SAICAR synthetase domain, 267-425 is the AIR carboxylase domain, and the two domains are linked by the 6-peptide (KSESQC).
  • KSESQC 6-peptide 6-peptide
  • the GLN159-GLN183 ⁇ helix of the SAICAR Synthetase domain interacts with the ASN395-ASN424 ⁇ helix of the AIR carboxylase domain, as shown in Figure 1.
  • the structure containing CAIR in the composite has 2GQS, 2CNQ and 4FE2
  • the structure containing ASP has 2CNV, 2CNU and 4FE2.
  • DB00127 (common name: Spermine, spermine) has a Dock Score of 316.723, indicating that the compound spermine can effectively interact with PAICS, affecting the synthesis of SAICAR, and is expected to be developed as a drug for the treatment of ADSL deficiency or to improve the health of ADSL deficiency.
  • the pharmaceutically acceptable derivative of the above compound has the same core structure as the compound itself, and undergoes hydrolysis or the like in the body to form a molecule having the same or similar activity as the original compound, achieving the same or similar therapeutic effects.
  • a pharmaceutically acceptable derivative of a compound especially a simple derivative thereof, particularly one of a lower ester, a lower ether, a lower alkyl substituent, a pharmaceutically acceptable salt, or a lower amide, that is, having 1 to 6 carbon atoms. It is preferably a derivative obtained by condensing a carboxylic acid, an alcohol or an amine of 2 to 6, 2 to 4 with a parent compound.
  • compositions of the compounds can be synthesized from the parent compound by conventional chemical methods, such as in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich Stahl (Editor), Camille G. Wermuth (Editor), ISBN: The method described in 3-90639-026-8, Hardcover, 388 pages, August 2002.
  • these salts can be prepared by reacting the free base of the compound with an acid in water or an organic solvent or a mixture of the two; usually, A non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol or acetonitrile is used.
  • Acid addition salts can be prepared by various acids (mineral acids and organic acids).
  • the acid addition salt include a salt made of an acid selected from the group consisting of acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid (e.g., L-ascorbic acid), and L-aspartate.
  • benzenesulfonic acid benzoic acid, 4-acetamidobenzoic acid, butyric acid, (+) camphoric acid, camphor-sulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, citric acid, hexanoic acid, Octanoic acid, cinnamic acid, citric acid, cyclaic acid, lauryl sulfate, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethylsulfonic acid, formic acid, fumaric acid, galactose Acid, gentisic acid, glucoheptonic acid, D-gluconic acid, glucuronic acid (such as D-glucuronic acid), glutamic acid (such as L-glutamic acid), ⁇ -ketoglutaric acid, glycolic acid, Hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionate
  • Combination therapy can improve the efficacy and reduce side effects.
  • two, three, four, five or more compounds or derivatives thereof can be used simultaneously as an active ingredient for treating ADSL deficiency.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Birds (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

提供了精胺及其衍生物的应用。基于现有的蛋白结构数据、小分子结构数据，使用软件计算分析，筛选得到可以有效干扰PAICS活性的化合物，使用后可以减少SAICAR的合成，最终减少SAICAr的积累，达到治疗或减少ADSL缺陷症的目的。通过联合使用上述化合物中的至少两种，有望获得更佳的治疗或改善ADSL缺陷症的效果。

Description

精胺及其衍生物的新应用 技术领域
本发明涉及精胺及其衍生物的新应用。
背景技术
嘌呤合成代谢是生物体普遍存在而又十分重要的生物代谢，其产物AMP和GMP不仅为生物体内DNA和RNA的生物合成提供原料，而且也为体内许多关键的辅酶(NAD、NADP、FAD和CoA)、信号分子(如cAMP)和重要的能量分子ATP提供其合成所必需的嘌呤碱基。可见，嘌呤合成代谢在整个代谢网络中处于核心位置。嘌呤合成包括从头合成(de novo purine synthesis)和补救途径(salvage pathway)两个合成途径。
腺苷酸琥珀酸裂解酶缺陷症(adenylosuccinatelyase deficiency ADSL缺陷症)是一种在腺嘌呤从头合成以及嘌呤核苷酸代谢途径中产生缺失、混乱的代谢疾病。该疾病产生的原因主要是由于患者体内的腺苷酸琥珀酸裂解酶发生了突变或者缺失，从而导致细胞中该酶的底物SAICAR过度地积累而得不到及时的清除[Jaeken J，Van den Berghe G.(1984).An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids.Lancet 8411：1058-1061.]。1984年Jaeken以及Van den Berghe首次在几个患有运动迟缓症和自闭症的患者体液中检测到该代谢物的积累。患有腺苷酸琥珀酸裂解酶缺陷症的患者通常会出现严重的发育不良、运动迟缓、目光呆滞、癫痫、自闭等症状[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinatelyase deficiency.Mol Genet Metab 89，19-31.Clamadieu，C.，Cottin，X.，Rousselle，C.，and Claris，O.(2008).Adenylosuccinatelyase deficiency：an unusual cause of neonatal seizure.Arch Pediatr 15，135-138.Castro，M.，Perez-Cerda，C.，Merinero，B.，Garcia，M.J.，Bernar，J.，Gil Nagel，A.，Torres，J.，Bermudez，M.，Garavito，P.，Marie，S.，et al.(2002).Screening for adenylosuccinatelyase deficiency：clinical，biochemical and molecular findings in four patients.Neuropediatrics 33，186-189.Jurecka，A.，Zikanova，M.，Tylki-Szymanska，A.，Krijt，J.，Bogdanska，A.，Gradowska，W.，Mullerova，K.，Sykut-Cegielska，J.，Kmoch，S.，and Pronicka，E.(2008b).Clinical，biochemical and molecular findings in seven Polish patients with adenylosuccinatelyase deficiency.Mol Genet Metab 94，435-442.]。
ADSL缺陷症有3种连续的主要表型：新生儿致死型、重度(I型)和轻到中度(II型)。临床上发现即便是来自同一家族的患者也具有不同的表型。发病一般见于出生至婴幼儿期。已报导的病例有致死的新生脑病变(表现有运动功能减退、难治性癫痫、呼吸障碍)，中度智 力缺陷。所有的患者均存在智力缺陷，大多数存在不同类型的癫痫，约1/3的存在自闭症特征(无法进行眼神交流、对声光敏感、重复性行为、躁动、乱发脾气、自伤和自残)。其他不常见的临床表现包括心理运动延迟、过度活跃、语言障碍、肌肉张力减退、肌肉萎缩和痉挛。重度患者通常小头畸形。产前临床表现报导的有：宫内生长受损、小头畸形、胎儿运动功能减退以及胎儿心率变化缺失。
在腺嘌呤从头合成的代谢途径中，腺苷酸琥珀酸裂解酶(以下简称ADSL酶)主要参与将SAICAR裂解催化形成AICAR以及S-AMP生成AMP的反应[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinatelyase deficiency.Mol Genet Metab 89，19-31.Clamadieu，C.，Cottin，X.，Rousselle，C.，and Claris，O.(2008).Adenylosuccinatelyase deficiency：an unusual cause of neonaal seizure.Arch Pediatr 15，135-138.Castro，M.，Perez-Cerda，C.，Merinero，B.，Garcia，M.J.，Bernar，J.，Gil Nagel，A.，Torres，J.，Bermudez，M.，Garavito，P.，Marie，S.，et al.(2002).Screening for adenylosuccinatelyase deficiency：clinical，biochemical and molecular findings in four patients.Neuropediatrics 33，186-189.]。腺苷酸琥珀酸裂解酶缺陷患者由于ADSL酶发生了突变或者缺失，导致有害代谢物SAICAR得不到及时的清除，通常会出现很严重的神经以及生理的症状，比如癫痫，大脑发育失常，运动呆滞等[Ciardo，F.，Salerno，C.，and Curatolo，P.(2001).Neurologic aspects of adenylosuccinatelyase deficiency.J Child Neurol 16，301-308.Gitiaux，C.，Ceballos-Picot，I.，Marie，S.，Valayannopoulos，V.，Rio，M.，Verrieres，S.，Benoist，J.F.，Vincent，M.F.，Desguerre，I.，and Bahi-Buisson，N.(2009).Misleading behavioural phenotype with adenylosuccinatelyase deficiency.Eur J Hum Genet 17，133-136.Mierzewska，H.，Schmidt-Sidor，B.，Jurkiewicz，E.，Bogdanska，A.，Kusmierska，K.，and Stepien，T.(2009).Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinatelyase deficiency--MRI，clinical，biochemical and neuropathological findings of Polish patients.Folia Neuropathol 47，314-320.]。在患者的脑脊液、体液中，通常会大量积累中间代谢物SAICAr及S-Ado(SAICAr是SAICAR脱去磷酸的产物，S-Ado是S-AMP去磷酸的产物)[Spiegel，E.K.，Colman，R.F.，and Patterson，D.(2006).Adenylosuccinatelyase deficiency.Mol Genet Metab 89，19-31.Mierzewska，H.，Schmidt-Sidor，B.，Jurkiewicz，E.，Bogdanska，A.，Kusmierska，K.，and Stepien，T.(2009).Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinatelyase deficiency--MRI，clinical，biochemical and neuropathological findings of Polish patients.Folia Neuropathol 47，314-320.]。Van den Berghe等人发现体液中S-do与SAICAr的比值与患者的病症严重性有一定的相关性[Van den Bergh F，Vincent MF，Jaeken J，Van den Berghe G.(1993).Residual adenylosuccinase activities in fibroblasts of adenylosuccinase-deficient  children：parallel deficiency with adenylosuccinate and succinyl-AICAR in profoundly retarded patients and non-parallel deficiency in a mildly retarded girl，J.Inherit.Metab.Dis.16(2)415-424.]。目前，临床上并没有有效的，可以治愈ADSL缺陷症治疗方案。
氨基咪唑琥珀基氨甲酰核苷酸合成酶/氨基咪唑核苷酸羧化酶，即PAICS(phosphoribosylaminoimidazolesuccinocarboxamidesynthetase/phosphoribosylaminoimidazolecarboxylase)是一种嘌呤从头合成途径中重要的双功能酶，它具有SAICAR合成酶(4-(N-succinylcarboxamide)-5-aminoimidazole ribonucleotidesynthetase，SAICARs)和AIR羧化酶(5-aminoimidazole ribonucleotidecarboxylase，AIRc)的功能，催化嘌呤从头合成代谢第六步、第七步反应，其中的一个关键反应过程如下所示
Figure PCTCN2017101059-appb-000001
发明人在先的研究表明，通过干扰PAICS蛋白(基因)的功能，可以有效减少SAICAR及SAICAr的积累，达到治疗或改善ADSL缺陷症的目的，但是现阶段并未报导有相应的化合物具有这一作用。
精胺(Spermine)
Figure PCTCN2017101059-appb-000002
是含有两个氨基和两个亚氨基的多胺类物质，在生物体内由腐胺(丁二胺)和S-腺苷蛋氨酸经多种酶催化后生成。它与亚精胺都存在于细菌和大多数动物细胞中，是促进细胞增殖的重要物质。在酸性条件下，它呈现出多阳离子多胺类特性，并能与病毒与细菌中DNA结合。使DNA分子具有更大的稳定性与柔韧性，也是细胞培养液中必要组分之一。精胺已经有被作用营养补充剂使用。
发明内容
本发明的目的在于提供精胺及其衍生物的新应用。
发明人基于现有的蛋白结构数据、小分子结构数据，使用软件计算分析，发现DrugBank ID为DB00127的化合物(精胺)，可以有效干扰PAICS的活性，进而减少SAICAR的合成，最终减少SAICAr的积累，达到治疗或改善ADSL缺陷症的目的。
上述化合物药学上可接受的衍生物，具有与化合物本身相同的母核结构，在体内经过水解等作用，可以生成与原化合物具有相同或相近活性的分子，达到相同或相近的治疗效果。
化合物药学上可接受的衍生物，尤其指其简单衍生物，特别是其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种，即碳原子数在1～6，优选为2～6，2～4的羧酸、 醇、胺与母化合物缩合得到的衍生物。
化合物药学上可接受的药用盐可以通过常规的化学方法从母体化合物合成，如在Pharmaceutical Salts：Properties，Selection，and Use，P.Heinrich Stahl(Editor)，Camille G.Wermuth(Editor)，ISBN：3-90639-026-8，Hardcover，388pages，August 2002中描述的方法。一般来说，这些盐可以由化合物的游离碱和酸在水或有机溶剂或二者的混合液中反应制得；通常，使用非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈。
酸加成盐可以通过各种酸(无机酸和有机酸)制得。酸加成盐的实例包括由酸制成的盐，所述酸选自由乙酸、2，2-二氯乙酸、己二酸、藻酸、抗坏血酸(如L-抗坏血酸)、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、丁酸、(+)樟脑酸、樟脑-磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环拉酸、十二烷基硫酸、乙烷-1，2-二磺酸、乙烷磺酸、2-羟乙基磺酸、甲酸、富马酸、半乳糖酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、葡萄糖醛酸(如D-葡萄糖醛酸)、谷氨酸(如L-谷氨酸)、α-酮戊二酸、乙醇酸、马尿酸、氢溴酸、盐酸、氢碘酸、羟乙磺酸、(+)-L-乳酸、(±)-DL-乳酸、乳糖酸、马来酸、苹果酸、(-)-L-苹果酸、丙二酸、(±)-DL-扁桃酸、甲基磺酸、萘-2-磺酸、萘-1，5-二磺酸、1-羟基-2-萘酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、帕莫酸、磷酸、丙酸、L-焦谷氨酸、水杨酸、4-氨基-水杨酸、癸二酸、硬脂酸、丁二酸、硫酸、单宁酸、(+)-L-酒石酸、硫氰酸、p-甲苯磺酸、十一碳烯酸和戊酸，以及酰化氨基酸和阳离子交换树脂组成的组。
通过联合使用上述化合物中的至少两种，有望获得更佳的治疗或改善ADSL缺陷症的效果。
附图说明
图1是PAICS的三维彩带(solid ribbon)结构图；
图2是CAIR和SAICAR合成酶在晶体结构中的相互作用图，图中A：PDB access ID 2GQS；B：PDB access ID 2CNQ；C：PDB access ID 4FE2；
图3是不同种SAICAR合成酶蛋白序列对齐结果。
具体实施方式
人PAICS蛋白质序列全长425个氨基酸残基，其中2～260AA为SAICAR synthetase结构域，267-425为AIR carboxylase结构域，两结构域由6肽(KSESQC)连接。此外，SAICAR Synthetase结构域的GLN159～GLN183α螺旋和AIR carboxylase结构域的ASN395～ASN424α螺旋相互作用，紧密结合这一起，如图1所示。
在蛋白质结构数据库中(RCSB)，收录了不同来源的SAICAR synthetase晶体结构数据，其中包括Saccharomyces cerevisiae(1A48，2CNQ，2CNV，2CNU，1OBD，1OBG)、 Pyrococcushorikoshii OT3(3U54，3U55)、Escherichia coli(2GQR，2GQS)、Methanocaldococcusjannaschii(2YZL，2Z02)、Streptococcus pneumonia(4FGR，4FE2)、Mycobacterium abscessus ATCC 19977/DSM 44196(3R9R)、Thermotoga maritime(1KUT)、Clostridium perfringens(3NUA)、Ehrlichiachaffeensis(3KRE)、Geobacilluskaustophilus(2YWV)。以及PAICS晶体结构数据Homo sapiens(2H31)和Bombyxmori(4JA0)。其中复合物中含有CAIR的结构有2GQS、2CNQ和4FE2，含有ASP的结构有2CNV、2CNU和4FE2。
如图2，在2CNQ中CAIR 
Figure PCTCN2017101059-appb-000003
以内的残基Arg122、Ser128、ASP215、Arg242和Arg264；2GQS中CAIR 
Figure PCTCN2017101059-appb-000004
以内的残基Arg94、Ser100、ASP129、ASP175、Arg199和Arg215；4FE2中CAIR 3埃以内的残基Arg93、Ser99、ASP174、Arg199、Arg214。对照不同物种来源的SAICAR蛋白序列对齐结果(图3)，可以看出不同物种SAICAR synthetase与CAIR的结合呈现高度保守性，主要以氢键作用固定CAIR。
基于以上结果，同时考虑到人的PAICS晶体结构中没有结合CAIR的构象，催化区域没有形成催化构象。进行计算筛选得到的结果不可靠。因此采用Saccharomyces cerevisiae(PDB：2CNQ)和Escherichia coli(PDB：2GQS)SAICAR合成酶晶体结构中的构象作为计算筛选的受体结构。采用Discovery studio的ligand fit模块，对DrugBank(http://www.drugbank.ca/downloads#structures)中的4661种小分子药物进行计算筛选。计算结果表明DB00127(通用名：Spermine，精胺)的Dock Score为316.723，表明化合物精胺可以有效与PAICS作用，影响SAICAR的合成，有望开发为治疗ADSL缺陷症的药物或改善ADSL缺陷症的保健品。
进一步的生化酶活实验、细胞生物学实验确证，化合物精胺对SAICAR的蓄积抑制率可以达到71.1％，通过对PAICS活性的抑制，导致有毒化合物SAICAR的蓄积下降，从而证明可以有效治疗罕见病ADSL缺陷症。
上述化合物药学上可接受的衍生物，具有与化合物本身相同的母核结构，在体内经过水解等作用，可以生成与原化合物具有相同或相近活性的分子，达到相同或相近的治疗效果。
化合物药学上可接受的衍生物，尤其指其简单衍生物，特别是其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种，即碳原子数在1～6，优选为2～6，2～4的羧酸、醇、胺与母化合物缩合得到的衍生物。
化合物药学上可接受的药用盐可以通过常规的化学方法从母体化合物合成，如在Pharmaceutical Salts：Properties，Selection，and Use，P.Heinrich Stahl(Editor)，Camille G.Wermuth(Editor)，ISBN：3-90639-026-8，Hardcover，388pages，August 2002中描述的方法。一般来说，这些盐可以由化合物的游离碱和酸在水或有机溶剂或二者的混合液中反应制得；通常， 使用非水介质如乙醚、乙酸乙酯、乙醇、异丙醇或乙腈。
酸加成盐可以通过各种酸(无机酸和有机酸)制得。酸加成盐的实例包括由酸制成的盐，所述酸选自由乙酸、2，2-二氯乙酸、己二酸、藻酸、抗坏血酸(如L-抗坏血酸)、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、丁酸、(+)樟脑酸、樟脑-磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、己酸、辛酸、肉桂酸、柠檬酸、环拉酸、十二烷基硫酸、乙烷-1，2-二磺酸、乙烷磺酸、2-羟乙基磺酸、甲酸、富马酸、半乳糖酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、葡萄糖醛酸(如D-葡萄糖醛酸)、谷氨酸(如L-谷氨酸)、α-酮戊二酸、乙醇酸、马尿酸、氢溴酸、盐酸、氢碘酸、羟乙磺酸、(+)-L-乳酸、(±)-DL-乳酸、乳糖酸、马来酸、苹果酸、(-)-L-苹果酸、丙二酸、(±)-DL-扁桃酸、甲基磺酸、萘-2-磺酸、萘-1，5-二磺酸、1-羟基-2-萘酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、帕莫酸、磷酸、丙酸、L-焦谷氨酸、水杨酸、4-氨基-水杨酸、癸二酸、硬脂酸、丁二酸、硫酸、单宁酸、(+)-L-酒石酸、硫氰酸、p-甲苯磺酸、十一碳烯酸和戊酸，以及酰化氨基酸和阳离子交换树脂组成的组。
组合用药在一定程度上可以提高疗效，减少毒副作用。优选的，可以同时使用2种、3种、4种、5种或更多种化合物或其衍生物作为治疗ADSL缺陷症的活性成分。

Claims (15)

  1. 化合物或其药学上可接受的衍生物在制备SAICAR合成酶活性干扰剂或抑制剂中的应用，其中，化合物为精胺。
  2. 根据权利要求1所述的应用，其特征在于：SAICAR合成酶为PAICS。
  3. 根据权利要求1所述的应用，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  4. 根据权利要求3所述的应用，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  5. 化合物或其药学上可接受的衍生物在制备ADSL缺陷症治疗或缓解药物或保健品中的应用，其中，化合物为精胺。
  6. 根据权利要求5所述的应用，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  7. 根据权利要求6所述的应用，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  8. 一种治疗或缓解ADSL缺陷症的组合物，其特征在于：其活性成分选自精胺及其药学上可接受的衍生物中的至少两种。
  9. 根据权利要求8所述的组合物，其特征在于：其活性成分选自精胺及其药学上可接受的衍生物中的至少3种。
  10. 根据权利要求8或9所述的组合物，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  11. 根据权利要求10所述的组合物，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
  12. 根据权利要求8所述的组合物，其特征在于：组合物还包括药学或食品上可接受的辅料。
  13. 治疗或缓解ADSL缺陷症的方法，包括给予患者治疗量的化合物或其药学上可接受的衍生物，其中，化合物为精胺。
  14. 根据权利要求13所述的方法，其特征在于：化合物药学上可接受的衍生物为其简单衍生物。
  15. 根据权利要求13所述的方法，其特征在于：简单衍生物为其低级酯、低级醚、低级烷基取代物、药用盐、低级酰胺中的一种。
PCT/CN2017/101059 2016-09-29 2017-09-08 精胺及其衍生物的新应用 WO2018059211A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP17854661.0A EP3520770A4 (en) 2016-09-29 2017-09-08 NEW APPLICATIONS OF SPERMINE AND DERIVATIVES THEREOF
JP2019516530A JP6870077B2 (ja) 2016-09-29 2017-09-08 スペルミン及びその誘導体の新たな使用
US16/334,273 US10709676B2 (en) 2016-09-29 2017-09-08 Applications of spermine and derivatives thereof
US16/889,500 US20200297660A1 (en) 2016-09-29 2020-06-01 Applications of spermine and derivatives thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610865149.5 2016-09-29
CN201610865149 2016-09-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/334,273 A-371-Of-International US10709676B2 (en) 2016-09-29 2017-09-08 Applications of spermine and derivatives thereof
US16/889,500 Division US20200297660A1 (en) 2016-09-29 2020-06-01 Applications of spermine and derivatives thereof

Publications (1)

Publication Number Publication Date
WO2018059211A1 true WO2018059211A1 (zh) 2018-04-05

Family

ID=61762483

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CN2017/101060 WO2018059212A1 (zh) 2016-09-29 2017-09-08 减少saicar累积的化合物及应用
PCT/CN2017/101061 WO2018059213A1 (zh) 2016-09-29 2017-09-08 干扰saicar合成的化合物及应用
PCT/CN2017/101059 WO2018059211A1 (zh) 2016-09-29 2017-09-08 精胺及其衍生物的新应用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/CN2017/101060 WO2018059212A1 (zh) 2016-09-29 2017-09-08 减少saicar累积的化合物及应用
PCT/CN2017/101061 WO2018059213A1 (zh) 2016-09-29 2017-09-08 干扰saicar合成的化合物及应用

Country Status (4)

Country Link
US (2) US10709676B2 (zh)
EP (1) EP3520770A4 (zh)
JP (1) JP6870077B2 (zh)
WO (3) WO2018059212A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613416A4 (en) * 2017-04-20 2020-10-21 Geneheal Biotechnology Co., Ltd. APPLICATION OF SPERMINE AND ITS DERIVATIVES IN THE PREPARATION OF AN ANTI-CANCER DRUG
US11517541B2 (en) 2017-04-20 2022-12-06 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
US11766412B2 (en) 2016-09-29 2023-09-26 Geneheal Biotechnology Co., Ltd. Methods of treating or alleviating adenylosuccinatelyase (ADSL) deficiency using spermidine or a pharmaceutically acceptable salt of spermidine

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018192318A1 (zh) * 2017-04-20 2018-10-25 广州君赫生物科技有限公司 干扰saicar合成酶活性化合物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242701A1 (en) * 2001-09-24 2004-12-02 Norberto Bilbeny Lojo Amines as ant-alcoholism agents
CN1829496A (zh) * 2003-07-31 2006-09-06 朱利亚尼股份公司 精胺和/或亚精胺在食用、药用或美容用组合物中对抗皮肤老化的用途
WO2014067038A1 (zh) * 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 治疗人类adsl缺陷症的靶点、制剂及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037371A2 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Amp-kinase agonists or adenosine pro-drugs as immuno-stimulating agents
CN101205555A (zh) * 2006-12-18 2008-06-25 中国疾病预防控制中心寄生虫病预防控制所 抗日本血吸虫药物作用靶标、药物筛选方法及药物先导化合物
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
RU2014102629A (ru) * 2011-06-29 2015-08-10 Зе Орегон Стейт Боард Оф Хайе Эдьюкейшн Он Бехалф Оф Портланд Стейт Юниверсити Выявление аналита с использованием флуорофоров ближней инфракрасной области
US20160369281A1 (en) * 2015-06-16 2016-12-22 Geneheal Biotechnology Co., Ltd. Target point, preparation and method for treating human ADSL deficiency

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242701A1 (en) * 2001-09-24 2004-12-02 Norberto Bilbeny Lojo Amines as ant-alcoholism agents
CN1829496A (zh) * 2003-07-31 2006-09-06 朱利亚尼股份公司 精胺和/或亚精胺在食用、药用或美容用组合物中对抗皮肤老化的用途
WO2014067038A1 (zh) * 2012-10-29 2014-05-08 广州百赫医疗信息科技有限公司 治疗人类adsl缺陷症的靶点、制剂及方法

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Salts: Properties, Selection and Use", August 2002, pages: 388
CASTRO, M.; PEREZ-CERDA, C.; MERINERO, B.; GARCIA, M.J.; BEMAR, J.; GIL NAGEL, A.; TORRES, J.; BERMUDEZ. M.; GARAVITO, P.; MARIE.: "Screening for adenylosuccinatelyase deficiency: clinical, biochemical and molecular findings in four patients", NEUROPEDIATRICS, vol. 33, 2002, pages 186 - 189
CASTRO. M.; PEREZ-CERDA, C.; MERINERO, B.; GARCIA. M.J.; BEMAR. J.; GIL NAGEL, A.; TORRES. J.; BERMUDEZ. M.; GARAVITO. P.; MARIE.: "Screening for adenylosuccinatelyase deficiency: clinical, biochemical and molecular findings in four patients", NEUROPEDIATRICS, vol. 33, 2002, pages 186 - 189
CHIPPERFIEL, J. R. ET AL.: "Effects on the Activity of the Enzyme Phosphoribo-syl-Aminoimidazole Carboxylase, ...... 5-Amino-l- 0 -D-Ribofuranosylimidazo-le-4-Carboxylic Acid 5' -Phosphate", NUCLEOSIDES AND NUCLEOTIDES, vol. 7, no. 5, 6, 31 December 1988 (1988-12-31), pages 571 - 576, XP009514061, ISSN: 0732-8311, DOI: 10.1080/07328318808056287 *
CIARDO, F.; SALERNO.C.; CURATOLO, P.: "Neurologic aspects of adenylosuccinatelyase deficiency", J CHILD NEUROL, vol. 16, 2001, pages 301 - 308, XP008162221, DOI: doi:10.1177/088307380101600501
CLAMADIEU, C.; COTTIN, X.; ROUSSELLE, C.; CLARIS, O.: "Adenylosuccinatelyase deficiency: an unusual cause of neonatal seizure", ARCH PEDIATR, vol. 15, 2008, pages 135 - 138
CLAMADIEU. C.; COTTIN, X.; ROUSSELLE. C.; CLARIS. O.: "Adenylosuccinatelyase deficiency: an unusual cause of neonatal seizure", ARCH PEDIATR, vol. 15, 2008, pages 135 - 138
GITIAUX, C.; CEBALLOS-PICOT. I.; MARIE. S.; VALAYANNOPOULOS, V.; RIO, M.; VERRIERES, S.; BENOIST. J.F.; VINCENT, M.F.; DESGUERRE,: "Misleading behavioural phenotype with adenylosuccinatelyase deficiency", EUR J HUM GENET, vol. 17, 2009, pages 133 - 136
JAEKEN J; VAN DEN BERGHE G.: "An infantile autistic syndrome characterized by the presence of succinylpurines in body fluids", LANCET, vol. 8411, 1984, pages 1058 - 1061, XP055007074
JURECKA, A.; ZIKANOVA, M.; TYLKI-SZYMANSKA, A.; KRIJT, J.; BOGDANSKA, A.; GRADOWSKA, W.; MULLEROVA, K.; SYKUT-CEGIELSKA, J.; KMOCH: "Clinical, biochemical and molecular findings in seven Polish patients with adenylosuccinatelyase deficiency", MOL GENET METAB, vol. 94, 2008, pages 435 - 442, XP022833453, DOI: doi:10.1016/j.ymgme.2008.04.013
MACKENZIE, GRAHAME ET AL.: "Synthesis of Analogues of 5-Aminoimidazole Ri-bonucleotides and their Effects as Inhibitors and Substrates of the Enzymes , ...... Purine Nucleotides de novo", J. C. S. CHEM. COMM, vol. 12, 1 January 1976 (1976-01-01), pages 453 - 455, XP055500446, DOI: doi:10.1039/c39760000453 *
MIERZEWSKA, H.; SCHMIDT-SIDOR, B.; JURKIEWICZ, E.; BOGDANSKA, A.; KUSMIERSKA. K.; STEPIEN, T.: "Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinatelyase deficiency--MRI, clinical, biochemical and neuropathological findings of Polish patients", FOLIA NEUROPATHOL, vol. 47, 2009, pages 314 - 320
MIERZEWSKA. H.; SCHMIDT-SIDOR, B.; JURKIEWICZ, E.; BOGDANSKA, A.; KUSMIERSKA. K.; STEPIEN, T.: "Severe encephalopathy with brain atrophy and hypomyelination due to adenylosuccinatelyase deficiency--MRI, clinical, biochemical and neuropathological findings of Polish patients", FOLIA NEUROPATHOL, vol. 47, 2009, pages 314 - 320
PEGG, ANTHONY E.: "The Function of Spermine", IUBMB LIFE, vol. 1, 6 January 2014 (2014-01-06), pages 8 - 18, XP055582873, ISSN: 1521-6543, DOI: 10.1002/iub.1237 *
See also references of EP3520770A4
SPIEGEL, E.K.; COLMAN, R.F.; PATTERSON, D.: "Adenylosuccinatelyase deficiency", MOL GENET METAB, vol. 89, 2006, pages 19 - 31
SPIEGEL, E.K.; COLMAN. R.F.; PATTERSON, D.: "Adenylosuccinatelyase deficiency", MOL GENET METAB, vol. 89, 2006, pages 19 - 31
VAN DEN BERGH F; VINCENT MF. JAEKEN J; VAN DEN BERGHE G.: "Residual adenylosuccinase activities in fibroblasts of adenylosuccinase-deficient children: parallel deficiency with adenylosuccinate and succinyl-AICAR in profoundly retarded patients and non-parallel deficiency in a mildly retarded girl", J. INHERIT. METAB. DIS., vol. 16, no. 2, 1993, pages 415 - 424

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11766412B2 (en) 2016-09-29 2023-09-26 Geneheal Biotechnology Co., Ltd. Methods of treating or alleviating adenylosuccinatelyase (ADSL) deficiency using spermidine or a pharmaceutically acceptable salt of spermidine
EP3613416A4 (en) * 2017-04-20 2020-10-21 Geneheal Biotechnology Co., Ltd. APPLICATION OF SPERMINE AND ITS DERIVATIVES IN THE PREPARATION OF AN ANTI-CANCER DRUG
US11517541B2 (en) 2017-04-20 2022-12-06 Geneheal Biotechnology Co., Ltd. Applications of spermidine and its derivatives
US11684593B2 (en) 2017-04-20 2023-06-27 Geneheal Biotechnology Co., Ltd. Applications of spermine and its derivative in preparation of antitumor drug

Also Published As

Publication number Publication date
JP6870077B2 (ja) 2021-05-12
US20200297660A1 (en) 2020-09-24
JP2020502041A (ja) 2020-01-23
EP3520770A1 (en) 2019-08-07
EP3520770A4 (en) 2020-06-17
US20190209493A1 (en) 2019-07-11
US10709676B2 (en) 2020-07-14
WO2018059212A1 (zh) 2018-04-05
WO2018059213A1 (zh) 2018-04-05

Similar Documents

Publication Publication Date Title
US20200297660A1 (en) Applications of spermine and derivatives thereof
WO2018059215A1 (zh) 降低saicar累积的化合物及应用
US11549145B2 (en) Methods and compositions for inhibiting and treating neurological conditions
Berry The potential of trace amines and their receptors for treating neurological and psychiatric diseases
EP3613416B1 (en) Applications of spermine and its derivative in preparation of antitumor drug
WO2018192323A1 (zh) 亚精胺及其衍生物的应用
US20150190414A1 (en) Agent for ameliorating brain hypofunction
Cremonte et al. The Effect of experimental supplementation with the Klamath algae extract Klamin on attention-deficit/hyperactivity disorder
WO2019113724A1 (zh) 双硫仑的新应用
WO2019033257A1 (zh) 化合物干扰saicar合成酶活性的新应用
WO2022095809A1 (zh) 影响saicar表达量的化合物的新应用
WO2018192318A1 (zh) 干扰saicar合成酶活性化合物的应用
WO2020140730A1 (zh) 硫鸟嘌呤在制备治疗adsl缺陷症药物中应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17854661

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019516530

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017854661

Country of ref document: EP

Effective date: 20190429